Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.

ABSTRACT:

Background

Small cell lung cancer (SCLC) has a poor prognosis, and its treatment options are limited. Delta-like protein 3 (DLL3) is expressed specifically in SCLC and is considered a promising therapeutic target for patients with this disease. Rovalpituzumab tesirine (Rova-T) was the first antibody-drug conjugate targeting DLL3. Although Rova-T development was unfortunately terminated, DLL3 remains an ideal target for SCLC. Near infrared photoimmunotherapy (NIR-PIT) is a new form of cancer treatment that employs an antibody-photosensitiser conjugate followed by NIR light exposure and damage target cells specifically. In this study, we demonstrate DLL3-targeted NIR-PIT to develop a novel molecularly targeted treatment for SCLC.

Methods

The anti-DLL3 monoclonal antibody roval

SUBMITTER: Isobe Y 

PROVIDER: S-EPMC6992936 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature